NCCN Guidelines for Patients® | Non-Small Cell Lung Cancer - page 76

76
NCCN Guidelines for Patients
®
: Non-Small Cell Lung Cancer
Version 1.2014
Part 7: Treatment by cancer stage
Treatments after first line
EGFR and ALK status: Unknown or negative
Histology
Performance status score
Treatment options if cancer grows
during or after first-line treatments
Non-squamous
0, 1, or 2
Docetaxel,
Pemetrexed,
Erlotinib,
Gemcitabine,
Best supportive care, or
Clinical trial
3 or 4
Erlotinib if EGFR mutation, or
Best supportive care
Squamous
0, 1, or 2
Docetaxel,
Erlotinib,
Gemcitabine,
Best supportive care, or
Clinical trial
3 or 4
Erlotinib if EGFR mutation, or
Best supportive care
1...,66,67,68,69,70,71,72,73,74,75 77,78,79,80,81,82,83,84,85,86,...108
Powered by FlippingBook